The efficacy of adalimumab therapy in refractory hidradenitis suppurativa: Retrospective analysis Dirençli hidradenitis süpürativa olgularında adalimumab etkinliği: Retrospektif değerlendirme

TÜRKMEN M.

Turkderm Turkish Archives of Dermatology and Venereology, cilt.53, sa.3, ss.101-105, 2019 (Scopus, TRDizin)

Özet

Background and Design: Hidradenitis suppurativa (HS) is a painful, chronic, inflammatory skin disease and there is no effective standard method for its treatment. The studies on the successful results of adalimumab in the treatment of HS are increasing and its use is approved by the Ministry of Health in our country. Materials and Methods: The efficacy and side effects of adalimumab were evaluated retrospectively in 9 patients who were diagnosed with resistant HS. Adalimumab was administered 40 mg subcutaneously per week. Patients were followed closely for infections and other side effects. In patients, nodules, abscesses and fistulas were determined at the beginning of the treatment, at the 4th and 12th week of the treatment. The values of global pain scores, life quality index scores and C-reactive protein levels recorded at the beginning and at the 12th week of the treatment were evaluated. Results: The ages of 9 patients receiving adalimumab for severe HS were between 33-67 (mean: 50.6), and 7 of the patients were male. The disease duration ranged from 2 to 25 years (mean: 13 years) 5 of the patients according to the Hurley classification was determined as stage 2 and 4 as stage 3. In the 12th week, the number of nodules, abscess and draining fistulas were decreased respectively 60.2%, 69.3% and 52.1%. C-reactive protein levels of 16.3 mg/L at the beginning of treatment were 5.5 mg/L at 12 weeks. Before the treatment, life quality index score was 23.4, and after 12 weeks, the score decreased to 6.8. There was a significant improvement in the quality of life. Pain scores of 6.6±3.4 before the treatment were reduced to 1.5±2.5 in the 12th week of treatment. No side effects were observed during treatment. Coclusion: In this study, adalimumab was evaluated as an effective and well tolerated treatment option in moderate and severe HS.